We measured four chemokines in the cerebrospinal fluid (CSF) in human T-lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) with ELISA. CXCL10/IP-10, a T cell type 1 (Th1)-associated chemokine, was significantly elevated in HAM/TSP compared with controls, and the values were even significantly higher in HAM/TSP than in multiple sclerosis (MS) in which CXCL10/IP-10 up-regulation was previously reported. Among Th2-associated chemokines, CCL17/TARC and CCL11/Eotaxin in HAM/TSP were not different from those in controls. As shown in MS, CCL2/MCP-1 was significantly lower in HAM/TSP than in control. Following interferon (IFN)-alpha therapy in HAM/TSP, CCL2/MCP-1 became significantly higher than that before therapy, which may reflect a Th2 induction, while CXCL10/IP-10 remained elevated.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2004.10.011DOI Listing

Publication Analysis

Top Keywords

ham/tsp
6
csf-chemokines htlv-i-associated
4
htlv-i-associated myelopathy
4
myelopathy cxcl10
4
cxcl10 up-regulation
4
up-regulation therapeutic
4
therapeutic interferon-alpha
4
interferon-alpha measured
4
measured chemokines
4
chemokines cerebrospinal
4

Similar Publications

Article Synopsis
  • HTLV-1 is linked to serious health issues like Adult T-cell Leukemia/Lymphoma and HAM/TSP; thus, screening potential organ donors for the virus is vital due to high transmission risks, particularly in kidney transplant recipients.
  • A study at the Iranian Tissue Bank from 2014 to 2021 found that 3% of 3,814 potential organ/tissue donors tested positive for HTLV-1, with rates significantly dropping from 6% to 0.5% over the years.
  • Females showed a higher positivity rate (4%) than males (2%), and donors with brain death had a much lower infection rate (0.2%) compared to those with circulatory death (4%).
View Article and Find Full Text PDF

Human T-lymphotropic virus type 1 (HTLV-1), leads to adult T-cell lymphoma/leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in a minority of infected individuals. The virus promotes inflammation, a major factor in chronic disease progression. Probiotics' immune modulation and anti-inflammatory effects present a potential therapeutic intervention for HTLV-1-related conditions.

View Article and Find Full Text PDF
Article Synopsis
  • HTLV-1 is linked to diseases like adult T-cell leukemia and HTLV-1-associated myelopathy, prompting researchers to isolate a molecular clone from a patient with HAM/TSP.
  • This clone exhibits unique genetic features and viral mRNA patterns, indicating a potential connection to the development of HAM/TSP.
  • The study finds that while direct infection of primary T cells with HTLV-1 clones leads to limited cell growth, transmission from dendritic cells enhances long-term proliferation and supports latent infections.
View Article and Find Full Text PDF

HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive neurological disorder and shares many radiological and clinical features with other more prevalent myelopathies. Here, we quantified spinal cord and brain volumes in adults with HAM/TSP in comparison with healthy volunteers (HVs) and individuals diagnosed with relapsing-remitting or progressive multiple sclerosis (RRMS or P-MS). Clinical disability and MRI were assessed in 24 HVs, 43 HAM/TSP subjects, and 46 MS subjects.

View Article and Find Full Text PDF

Correlation Between TWEAK Serum Level and HTLV-1 Proviral Load in HAM/TSP.

Viral Immunol

November 2024

Department of Medical Microbiology (Bacteriology & Virology), Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

Human T-cell lymphotropic virus type-I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), the main neurological manifestation of HTLV-I, is a chronic inflammatory disease. Viral-host interaction and host genetics are two important contributors to the development of the HAM/TSP. This study was conducted to measure the serum level of tumor necrosis factor-alpha-like weak inducer of apoptosis (TWEAK) by ELISA method in three groups of participants including 34 HAM/TSP patients (HAM/TSP), 35 asymptomatic HTLV-1 carriers (ACs), and 20 healthy controls (HCs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!